spacer
home > pmps > spring 2018 > traceable and transparent
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Traceable and Transparent

Theft and counterfeiting are two of the greatest issues threatening the pharmaceutical industry today, with claims that dangerous counterfeit drugs represent 10-30% of drugs available in developing countries, according to the WHO (1). Further research also estimates the cost of pharmaceutical theft to shippers and transporters alone at $30 billion a year, with an average of $4 million per loss. A deficit clearly needs to be resolved.

The supply chain of the average pharmaceutical product, from creation to delivery, is also continuing to expand geographically, as well as the number of companies involved in the chain itself. Pharma companies are relying on more and more partners to enable each stage of production and delivery to be as effective as possible and cater to new demands in the market, which, in turn, is increasing the complexity of the supply chain. A variety of additional forces are creating further complexities and will require companies reassess their strategies moving forward (2).

More diverse product types and therapies with shorter lifecycles mean the storage and delivery of certain drugs have also been transformed. New methods have been integrated for assessing, approving, and monitoring medicines, which is impacting how transparent each company has to be in terms of the supply chain. Finally, greater public scrutiny in the sector as well as tougher environmental controls and regulations are affecting the manner in which companies bring products to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julie Hurley, Global Director for Enterprise Solutions at Unisys, has an extensive pharma and life sciences background, with almost 20 years’ consulting to major pharma, biotechnology, and devices organisations in areas of strategic planning, industry best practice and implementation planning. She holds a patent, Genomic Sequencing for Clinical Trials, and has published several white papers, advertorials, and points of view.
spacer
Julie Hurley
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement